{"url_path":"/sec/fth/8-k/2026-06-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-270330-index.html","accession_number":"0001193125-26-270330","cik":"0001829802","ticker":"FTH","issuer_name":"Faeth Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-270330-index.html","primary_entity_key":"0001829802","primary_entity_name":"Sensei Biotherapeutics, Inc."},"word_count":98,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits\n\n(d) Exhibits\n\n \n\nExhibit\n\nNumber\n\n  \n\nExhibit Description\n\n3.1\n  \n[Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Company, effective June 15, 2026](d144622dex31.htm)\n\n99.1\n  \n[Press Release, dated June 15, 2026](d144622dex991.htm)\n\n104\n  \nCover Page Interactive Data File (embedded with the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nFaeth Therapeutics, Inc.\n\nDate: June 15, 2026\n \n\n \n\n \n\n/s/ Christopher W. Gerry\n\n \n \n \n \n \n \nChristopher W. Gerry\n\n \n \n \n \n \n \nGeneral Counsel and Secretary"}